-
Mashup Score: 35
EQS-News: MorphoSys AG / Key word(s): Study results MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction 20.11.2023 / 22:29 CET/CEST The issuer is solely responsible for the
Source: www.morphosys.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 35
EQS-News: MorphoSys AG / Key word(s): Study results MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction 20.11.2023 / 22:29 CET/CEST The issuer is solely responsible for the
Source: www.morphosys.comCategories: General Medicine News, Hem/OncsTweet-
The BET proteins will always have a special place in my ❤️- so great to see them make a clinical difference in a haematological disease with clinical need. MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis https://t.co/qkpAy9n7jO
-
The BET proteins will always have a special place in my ❤️- so great to see them make a clinical difference in a haematological disease with clinical need. MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis https://t.co/qkpAy9n7jO